Paradoxical role of autophagy in the dysplastic and tumor-forming stages of hepatocarcinoma development in rats

Cell Death and Disease

Volumn 4, Issue 2, 2013, Pages

  Sun, K ^a,b   Guo, X L ^b,c   Zhao, Q D ^b   Jing, Y Y ^b   Kou, X R ^b   Xie, X Q ^a,b   Zhou, Y ^a   Cai, N ^a   Gao, L ^b   Zhao, X ^a   Zhang, S S ^b   Song, J R ^b   Li, D ^b,d   Deng, W J ^b   Li, R ^b   Wu, M C ^b   Wei, L X ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Hang Zhou Sanitarium of Navy   (China)

^d LIAOCHENG PEOPLE'S HOSPITAL   (China)

Author keywords

Autophagy; Different stages; Hepatocarcinoma development; Paradoxical role; ROS

Indexed keywords

CHLOROQUINE; CYTOKINE; DIETHYLNITROSAMINE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER GROWTH; CANCER STAGING; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DNA DAMAGE; INHIBITION KINETICS; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ANIMALS; ANTIOXIDANTS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHLOROQUINE; CYTOKINES; DIETHYLNITROSAMINE; DNA DAMAGE; LIVER; LIVER NEOPLASMS; MALE; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SURVIVAL RATE; UP-REGULATION;

RATTUS;

EID: 84875995650     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.35     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin 2010; 61: 69-90.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(5 Suppl 1): S5-S16.
3. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004; 6: 463-477.
4. Mizushima N. Autophagy: process and function. Genes Dev 2007; 21: 2861-2873.
5. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15: 5308-5316.
6. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003; 100: 15077-15082.
7. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112: 1809-1820.
8. Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol 2006; 8: 688-699.
9. Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 2007; 9: 1142-1151.
10. Marino G, Salvador-Montoliu N, Fueyo A, Knecht E, Mizushima N, Lopez-Otin C. Tissuespecific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/ autophagin-3. J Biol Chem 2007; 282: 18573-18583.
11. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S et al. Autophagydeficient mice develop multiple liver tumors. Genes Dev 2011; 25: 795-800.
12. Altman BJ, Jacobs SR, Mason EF, Michalek RD, MacIntyre AN, Coloff JL et al. Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. Oncogene 2011; 30: 1855-1867.
13. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011; 25: 460-470.
14. Wei H, Wei S, Gan B, Peng X, Zou W, Guan JL. Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev 2011; 25: 1510-1527.
15. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discovery 2007; 6: 304-312.
16. Rajewsky MF, Dauber W, Frankenberg H. Liver carcinogenesis by diethylnitrosamine in the rat. Science (New York, NY) 1966; 152: 83-85.
17. Nagata H, Hatano E, Tada M, Murata M, Kitamura K, Asechi H et al. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma. Hepatology (Baltimore, MD) 2009; 49: 1944-1953.
18. Huang KW, Huang YC, Tai KF, Chen BH, Lee PH, Hwang LH. Dual therapeutic effects of interferon-alpha gene therapy in a rat hepatocellular carcinoma model with liver cirrhosis. Mol Ther 2008; 16: 1681-1687.
19. Meng X, Riordan NH. Cancer is a functional repair tissue. Med Hypotheses 2006; 66: 486-490.
20. Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T et al. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology (Baltimore, MD) 2003; 37: 65-71.
21. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-1183.
22. Enzmann H, Kuhlem C, Loser E, Bannasch P. Damage to mitochondrial DNA induced by the hepatocarcinogen diethylnitrosamine in ovo. Mutation Res 1995; 329: 113-120.
23. Adam-Vizi V, Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci 2006; 27: 639-645.
24. Scherz-Shouval R, Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem Sci 2011; 36: 30-38.
25. Bechtel W, Bauer G. Modulation of intercellular ROS signaling of human tumor cells. Anticancer Res 2009; 29: 4559-4570.
26. Rabinowitz JD, White E. Autophagy and metabolism. Science (New York, NY) 2010; 330: 1344-1348.
27. Mathew R,White E. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr Opinion Genet Dev 2011; 21: 113-119.
28. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev 2011; 11: 85-95.
29. Rosenfeldt MT, Ryan KM. The multiple roles of autophagy in cancer. Carcinogenesis 2011; 32: 955-963.
30. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
31. Shimada M, Nakanishi M. DNA damage checkpoints and cancer. J Mol Histol 2006; 37: 253-260.
32. Lu J, Chew EH, Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 2007; 104: 12288-12293.
33. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
34. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469: 221-225.
35. Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208: 519-533.
36. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7: 97-110.
37. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-707.
38. Gibson SB. A matter of balance between life and death: targeting reactive oxygen species (ROS)-induced autophagy for cancer therapy. Autophagy 2010; 6: 835-837.
39. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R et al. A mitochondria-K channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11: 37-51.